Company news

Trevi Therapeutics, Inc. news in 2022

Trevi Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Trevi Therapeutics to Present and Participate in Upcoming Conferences in San Francisco During the 41st Annual J.P. Morgan Health Care Conference

December 18, 2022

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

November 13, 2022

Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Trevi Therapeutics to Participate at the Stifel 2022 Healthcare Conference

November 7, 2022

Trevi Therapeutics to Report Q3 2022 Financial Results and Provide a Corporate Update on November 10, 2022

November 2, 2022

Trevi Therapeutics to Present Final Data from Phase 2 Trial of Oral Nalbuphine Extended Release for Chronic Cough in IPF at BTS' Winter Meeting

October 26, 2022

Correction: Trevi Therapeutics, Inc.

September 22, 2022

Trevi Therapeutics Announces Proposed Public Offering

September 21, 2022

Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

September 18, 2022

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022

Trevi Therapeutics to Host Virtual R&D Day on September 19, 2022

August 29, 2022

Trevi Therapeutics Announces Multiple Late-Breaking Abstracts Accepted for Presentation at Upcoming Medical Conferences on Analysis of Oral Nalbuphine Extended Release

August 23, 2022

Trevi Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

August 10, 2022

Trevi Therapeutics to Present at Upcoming August Conferences

August 8, 2022

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

August 3, 2022

Trevi Therapeutics to Attend the Twelfth London International Cough Symposium (12th LICS)

July 6, 2022

Trevi Therapeutics Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvio™ in the Treatment of Prurigo Nodularis

June 28, 2022

Trevi Therapeutics to Present and Participate in Partnership Meetings at Upcoming 2022 BIO International Convention

June 6, 2022

Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update

May 11, 2022

Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022

May 4, 2022

Trevi Therapeutics to Present at Upcoming May Meetings

May 2, 2022

Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

April 10, 2022

Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market

April 6, 2022

Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

March 21, 2022

Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update

March 16, 2022

Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough

March 14, 2022

Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022

March 8, 2022

Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

February 23, 2022

Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

January 31, 2022

Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

January 4, 2022

Calls in 2022

Decks in 2022